The TB Alliance Board of Directors recently welcomed new members: Dr. Bruce Carter, Dr. Lee Reichman and Mr. Parag Saxena have been appointed as new Directors, serving three-year terms. Dr. Carlos Morel has been re-appointed for a second term, and Dr. Charles Y. Yu, the newly-elected President of the TB Alliance Stakeholders Association, will serve as an ex-officio member on the Board for the duration of his two-year presidency.
Dr. Bruce Carter is President and CEO of Seattle-based ZymoGenetics, a leading American biotechnology company that develops drugs to treat a range of medical conditions, including bleeding disorders, autoimmune diseases and cancer. Responsible for leading the company’s spin-off from Novo Nordisk in 2000, Dr. Carter has transformed Zymogenetics from an early research enterprise to a solid product development company. A British citizen, Dr. Carter is widely recognized for his solution- oriented strategies and also serves on the Boards of BIO (Biotechnology Industry Organization) and WBBA (Washington Biotechnology & Biomedical Association).
Dr. Lee Reichman is Executive Director of the New Jersey Medical School National Tuberculosis Center. A globally recognized TB expert, Dr. Reichman brought widespread attention to the TB epidemic with his critically acclaimed book, Timebomb, The Global Epidemic of Multidrug Resistant Tuberculosis in 2001. Dr. Reichman previously served as an ex-officio Board member as the President of the Stakeholders Association from 2002-2004.
Mr. Parag Saxena is a seasoned venture capitalist and managing partner and CEO of INVESCO Private Capital, one of the world's largest independent asset management companies. Mr. Saxena has been involved in more than 300 private transactions, and has led investments in many companies, including those in the healthcare and pharmaceutical sectors, that have since gone public. He also sits on the board of Transgenomic and several private company boards, and is President of The Indus Entrepreneurs (TiE) for the Tri-State region, as well as a Trustee of the New York-based Bharatiya Vidya Bhawan, a prominent Indian cultural institution.
Dr. Charles Y. Yu, who was elected President for a two-year term during the Stakeholders Association Meeting in October 2004, is a TB expert with more than 15 years of experience in medicine, medical research, policy, and management of TB programs. Dr. Yu also serves as national chairman of the Manila-based Philippine Coalition Against Tuberculosis (PhilCAT), a coalition of 57 public and private sector organizations.
The TB Alliance Board of Directors consists of 10 directors elected for staggered three-year terms and assumes fiduciary responsibility for the TB Alliance. The Board guides the business strategy and reviews the strategies, actions and budgets of the TB Alliance.